GlassScriptPhysician profile
Katelin L Elenterio
NPI 1427612050
$10,617.90
in general payments reported to CMS, 2019-2025
31 companies · $2,172 in 2025
The $2,172 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,129 · 2022: $2,219 · 2023: $2,115 · 2024: $1,983 · 2025: $2,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,269.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,948.22 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,729.70 | 2021-2025 | Xifaxan, Trulance |
| Nestle Healthcare Nutrition INC. | $1,159.52 | 2021-2022 | |
| Qol Medical, LLC | $774.29 | 2023-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $724.01 | 2021-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $381.61 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $378.86 | 2021-2024 | Linzess |
| Lilly USA, LLC | $375.95 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $354.03 | 2023-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $298.01 | 2021-2024 | Dificid |
| Janssen Biotech, INC. | $297.05 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $271.89 | 2022-2024 | Dupixent |
| Pfizer INC. | $264.32 | 2022-2025 | |
| Gilead Sciences, INC. | $258.15 | 2021-2025 | |
| Vivus LLC | $207.10 | 2022-2025 | Qsymia, Pancreaze |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $200.89 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $185.03 | 2021-2025 | Ocaliva |
| Ferring Pharmaceuticals INC. | $149.71 | 2021-2023 | Rebyota |
| Argenx US, INC. | $131.88 | 2025 | Vyvgart |
| Braintree Laboratories, INC. | $98.57 | 2022-2024 | Suflave, Sutab |
| Celgene Corporation | $79.85 | 2022-2023 | Zeposia |
| Redhill Biopharma INC. | $77.41 | 2021-2023 | Aemcolo, Movantik, Talicia |
| Celltrion USA INC. | $68.64 | 2024-2025 | Vegzelma, Zymfentra |
| Aimmune Therapeutics, INC. | $50.66 | 2025 | Vowst, Zenpep |
| Alexion Pharmaceuticals, INC. | $32.28 | 2021 | |
| Alnylam Pharmaceuticals INC. | $27.40 | 2022 | |
| Mallinckrodt Hospital Products INC. | $26.31 | 2022 | |
| Madrigal Pharmaceuticals | $18.61 | 2025 | Rezdiffra |
| W. L. Gore & Associates, INC. | $18.45 | 2023 | Gore Cardioform Septal Occluder |
| Sandoz INC. | $15.69 | 2023 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.81 | 2024 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelin Elenterio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.